AIR 2, LLC™

VaporEFX™

Nicotine Reduction Platform

A Concise Comparative Overview

1+ (303) 324-7691

Robert@Air2Vapor.com

8100 S. Akron Street, No. 316
Centennial, Colorado 80112
USA

https://www.air2vapor.com/

Air2™ Nicotine Reduction Platform

Comparative Overview vs. Nicotinell® / Nicorette® Oral Nicotine Sprays (Medical, Regulatory & IP Focused – Inhaler Differentiation Included)

Purpose

This document provides a concise comparative overview of the product performance, formulation, intellectual property, and regulatory positioning of the Air2™ inhaler and sublingual nicotine delivery platform relative to legacy oral nicotine spray products, including Nicotinell® and Nicorette® / QuickMist®.

Product & Therapeutic Differentiation

Legacy Oral Nicotine Sprays (Nicotinell® / Nicorette®)

Oral nicotine sprays deliver nicotine via oromucosal absorption, typically providing approximately 1 mg nicotine per spray. Therapeutic effect is driven by dose intensity and speed, placing these products within traditional nicotine replacement therapy (NRT).

Air2's VaporEFX Inhaler & Sublingual Platform

Air2 employs a proprietary micellized nicotine delivery system designed to improve nicotine bioavailability and user satisfaction while materially reducing total nicotine exposure. The inhaler format provides pulmonary sensory cues and behavioral ritual replacement without combustion, heating, or batteries.

Formulation & Excipient Profile

Oral Nicotine Sprays

These products rely on complex excipient systems including ethanol as a primary solvent and sensory contributor, resulting in repeated direct oromucosal exposure.

Formulation & Excipient Profile (Continued)

Air2's Formulation Approach

Air2's, VaporEFX formulations may include ethanol at low levels solely as a co-solvent to support micellized nicotine stability. Ethanol does not materially contribute to nicotine uptake or sensory reinforcement.

Medical Regulatory Comparison

Category	Nicotinell® / Nicorette® Oral Spray	VaporEFX™ Sublingual & Inhaler
Therapeutic Classification	Nicotine Replacement Therapy (NRT)	Nicotine Reduction Therapy
Primary Delivery route	Oromucosal Spray	Inhalation & Sublingual
Pulmonary Sensory Cue	None	Present (non-combustion inhalation)
Behavioral Ritual Replacement	Minimal	High (hand-to-mouth, inhale pattern)
Suitability Smoker Transition	Dual Use Limited	Strong
Typical Nicotine Per Use	~1 mg Per Spray	Lower Nicotine; Efficiency-Driven
Mechanism of Satisfaction	Rapid Nicotine Spike	Optimized Bioavailability & Sensory Cue
Combustion / Heating	None	None
Battery Dependence	None	None
Ethanol Presence	Yes	Yes (low-level)
Ethanol Functional role	Primary Solvent and Carrier	Formulation Co-Solvent Only
Ethanol Contribution	Drives Absorption and Sensory Burn	Does Not Drive Uptake or Reinforcement
Formulation Complexity	High	Reduced Excipient Burden
Patent Protection	Expired	3 Issued U.S. Patents
PCT / International IP	Withdrawn / Abandoned	Active PCT With Positive Examination
Generic Competition Risk	High	Low

Executive Takeaway

Air2's VaporEFX uniquely combines patented micellized nicotine delivery across both its non-combustion inhaler and sublingual platforms, preserving key behavioral and sensory cues while materially reducing nicotine exposure and offering a clean, IP-protected alternative to commoditized legacy oral sprays.